secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001558370-23-008673
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports Q1 net loss $22.6M; initiates Phase 2 trial for XTX202
--------------------------------------------------------------------

- Cash and cash equivalents $93.3M as of Mar 31, 2023; runway into Q2 2024.
- Phase 2 trial started for XTX202 (tumor-activated IL-2) in advanced RCC and melanoma.
- R&D expenses $16.1M, up from $14.9M, driven by clinical and manufacturing activities.
- Net loss $22.6M vs $21.4M in Q1 2022.
- Plan to report preliminary Phase 1 data for XTX101 (anti-CTLA-4) in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/0001558370-23-008673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/xlo-20230509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer